

Bioimmunotherapy of tuberculosis: co-treatment with recombinant mouse granulocyte-macrophage colony-stimulating factor and methionine-Enkephalin

Prashant Gupta
Ganpat University, India.



Abstract

Background: Tuberculosis (TB) is one of the world's deadliest diseases as one third of the world's population is infected with TB. The WHO TB statistics for India for 2017 give an estimated incidence figure of 2.8 million cases of TB. Bioimmunotherapy approach along with the conventional drug therapy can be a new approach to tackle the problems associated with TB treatment. rmGM-CSF can exert its bioimmunotherapeutic effect through three possible mechanisms viz. activation of effector functions of macrophages, regulation of cytokine network and nitric oxide production. m-ENK has been reported to modulate nitrite and TNF- α production, and effector functions of macrophages. Therefore, we postulate that rmGM-CSF and M-ENK co-treatment imparts protection against TB. **Materials & Methods:** Here, we have tested the M-ENK and rmGM-CSF combination at different concentration in mouse peritoneal macrophages infected with Mycobacterium tuberculosis (H37Ra) and calculate the % phagocytic by ZN staining and colony forming units **Results:** The different concentration of M-ENK (10^{-7} , 10^{-9} and 10^{-11} M) and rmGM-CSF (50 **Results:** The different concentration of M-ENK (10^{-7} , 10^{-9} and 10^{-11} M) and rmGM-CSF (50 pg/ml) were tested in mouse peritoneal macrophages in vitro and observed the phagocytosis process in experiments. The combined effect of M-ENK and rmGM-CSF at 50 pg/ml and 10^{-9} M dose showed maximum phagocytic activity (70-80 %) using intra-macrophage phagocytic assay on murine macrophages, in vitro. The reduction in colony forming units (cfu) was also observed in combined dose combination of the M-ENK and rmGM-CSF at 50 pg/ml and 10^{-9} M dose treatment. **Conclusion:** We conclude that Bioimmunotherapy with rmGM-CSF and M-ENKs co-treatment can be a possible alternative to control tuberculosis infection.

Keyword: Bioimmunotherapy, rmGM-CSF and M-ENK (methionine-Enkephalin)



Biography:

Mr. Prashant Gupta is working Assistant professor in department of Pharmacology, at Shree S. K. Patel College of Pharmaceutical Education & Research, GANPAT University, Mehsana Gujarat. He has submitted his PhD thesis from the department of Pharmacology and Toxicology. His role as a PhD research scholar at NIPER Mohali includes drug combination screening, handling of tuberculosis bacteria, primary cell line culture, working with endogenous opioids and peptide screening. His academic credentials include a B. Pharm from GGU (central university), Bilaspur; (2012), M. S. (Pharm.) in Regulatory Toxicology from NIPER, Mohali (2014). Previously, He has worked at Sun Pharmaceutical Industries Limited (Drug Safety Evaluation department, GLP), Gurugram for 14 months. At SUN Pharma, he involved in various toxicities studies (Acute, Repeated dose, 4 days, 14 days, 28 days), which includes animal handling, dosing, sample collection from study animals, blood withdrawal, necropsy, organ collection and weighing, data collection and report preparation. He is good at GraphPad Prism, ImageJ, TOPKAT, DEREK software's and well versed with MS-Office (Word, Excel, PowerPoint), which are very much required for research work. He has well skilled in retrieving data from databases like PubMed, ScienceDirect and Google Scholar etc. He had considerable theoretical exposure to Anatomy & Physiology in



Health and Disease, Clinical Pharmacology, Biotechnology, Pharm. Analysis etc. during his M.S. (Pharm.) and acquainted with the guidelines of OECD and ICH. He has and more than 6 years' experience in research & teaching (including Ph.D. tenure) in the Pharmacology & Toxicology area at different organizations.).

[33rd World Congress on Pharmacology](#); Webinar- August 26-27, 2020

Abstract Citation:

Prashant Gupta, Bio immunotherapy of tuberculosis: co-treatment with recombinant mouse granulocyte-macrophage colony-stimulating factor and methionine-Enkephalin Pharmacology 2020, 33rd World Congress on Pharmacology; Webinar - 26-27, 2020.

<https://pharmacology.pharmaceuticalconferences.com/abstract/2020/bioimmunotherapy-of-tuberculosis-co-treatment-with-recombinant-mouse-granulocyte-macrophage-colony-stimulating-factor-and-methionine-enkephalin>